Julie Decaris
Sr. CRC
Pediatrics
School of Medicine

Publications (4)

Top publication keywords:
Biological TransportEzetimibeGlucoseAzetidinesCholesterol, HDLGlucose Transporter Type 2Anticholesteremic AgentsApolipoprotein A-IAbsorptionLiverCholesterolInsulin-Secreting CellsSterolsFecesIntestinal Mucosa

• Inhibition of intestinal cholesterol absorption with ezetimibe increases components of reverse cholesterol transport in humans.
  Atherosclerosis 2013 Davidson MH, Voogt J, Luchoomun J, Decaris J, Killion S, Boban D, Glass A, Mohammad H, Lu Y, Villegas D, Neese R, Hellerstein M, Neff D, Musliner T, Tomassini JE, Turner S
• In vivo tissue cholesterol efflux is reduced in carriers of a mutation in APOA1.
  Journal of lipid research 2013 Holleboom AG, Jakulj L, Franssen R, Decaris J, Vergeer M, Koetsveld J, Luchoomun J, Glass A, Hellerstein MK, Kastelein JJ, Hovingh GK, Kuivenhoven JA, Groen AK, Turner SM, Stroes ES
• Hepatic glucose sensing is required to preserve β cell glucose competence.
  The Journal of clinical investigation 2013 Seyer P, Vallois D, Poitry-Yamate C, Schütz F, Metref S, Tarussio D, Maechler P, Staels B, Lanz B, Grueter R, Decaris J, Turner S, da Costa A, Preitner F, Minehira K, Foretz M, Thorens B
• Measurement of reverse cholesterol transport pathways in humans: in vivo rates of free cholesterol efflux, esterification, and excretion.
  Journal of the American Heart Association 2012 Turner S, Voogt J, Davidson M, Glass A, Killion S, Decaris J, Mohammed H, Minehira K, Boban D, Murphy E, Luchoomun J, Awada M, Neese R, Hellerstein M